Novartis is set to make an equity investment in Surface Oncology as part of the agreement, a year after taking part in the company's $35m series A round.
Pharmaceutical firm Novartis is set to make an equity investment in US-based cancer immunotherapy developer Surface Oncology as part of a broad strategic collaboration agreement worth up to $170m.
The agreement will involve the companies collaborating on immunotherapeutics that will target the tumour micro-environment as well as the interface of innate and adaptive immunity.
Novartis will be able to access Surface’s cancer immunotherapy pipeline, securing an exclusive worldwide license for its lead program and options to license up to three…
